A Phase 2 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 03 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results (At data cut-off: 9 Dec 2022; n=40) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 01 Aug 2022 Planned End Date changed from 20 Dec 2024 to 20 Dec 2025.